Activation of the unfolded protein response and alternative splicing of ATF6α in HLA-B27 positive lymphocytes  by Lemin, Andrew J. et al.
FEBS Letters 581 (2007) 1819–1824Activation of the unfolded protein response and alternative splicing of
ATF6a in HLA-B27 positive lymphocytes
Andrew J. Lemin1, Khalil Saleki1, Marcel van Lith, Adam M. Benham*
School of Biological and Biomedical Sciences, University of Durham, South Road, Durham DH1 3LE, England, United Kingdom
Received 2 February 2007; accepted 23 March 2007
Available online 4 April 2007
Edited by Felix WielandAbstract Misfolding of major histocompatibility complex
(MHC) class I molecules has been implicated in the rheumatic
autoimmune disease ankylosing spondylitis (AS), and has been
linked to the unfolded protein response (UPR) in rodent AS mod-
els. XBP1 and ATF6a are two important transcription factors
that initiate and co-ordinate the UPR. Here we show that misox-
idised MHC class I heavy chains activate XBP1 processing in a
similar manner to tunicamycin, with tunicamycin and dithiothre-
itol (DTT) inducing diﬀerential XBP1 processing. Unexpectedly,
ATF6a mRNA is alternatively spliced during reducing stress in
lymphocytes. This shorter ATF6a message lacks exon 7 and
may have a regulatory role in the UPR.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Controlled protein secretion by specialized cells like the B
cell requires the co-ordinated synthesis of endoplasmic reticu-
lum (ER) membranes, chaperones and folding factors. Termi-
nally misfolded proteins in the ER must be removed to prevent
chronic intracellular indigestion and the onset of apoptosis,
and this is monitored by the unfolded protein response
(UPR) [1]. The eukaryotic UPR consists of a number of spe-
cialized signaling molecules, including IRE1 [2], ATF6a [3,4]
and the transcription factor XBP1 [5]. XBP1 binds upstream
of a UPR target gene to initiate transcription, but only after
it has been activated by unconventional mRNA processing.
Activation of XBP1 mRNA is achieved by IRE1, which dime-
rises, autophosphorylates, and becomes active as a site-speciﬁc
endo-RNase when unfolded proteins accumulate in the ERAbbreviations: AS, ankylosing spondylitis; DTT, dithiothreitol; ER,
endoplasmic reticulum; ERSE ER, stress response element; GAMPO,
goat anti-mouse peroxidase; HLA, human leukocyte antigen; LPS,
lipopolysaccharide; MHC, major histocompatibility complex; NEM,
N-ethylmaleimide; PMA, phorbol myristate acetate; PVDF, polyvi-
nylidene ﬂuoride; RT-PCR, reverse transcriptase polymerase chain
reaction; UPR, unfolded protein response
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doi:10.1016/j.febslet.2007.03.069[6,7]. IRE1 is likely to bind unfolded proteins directly and is
kept in the inactive (monomeric) form by BiP.
Whereas XBP1 is a cytosolic/nuclear transcription factor
that is activated by IRE1, ATF6a can sense and initiate
UPR gene transcription directly. ATF6a is a member of the
ATF/CREB family of bZIP proteins [8] and the protein is
cleaved in the Golgi by regulated intra-membrane proteolysis
[9]. Stress-induced cleavage of the ATF6a precursor occurs
after dissociation from BiP [10], releasing a cytosolic fragment.
This liberated transcription factor can bind to consensus
ERSE sequences (with NF-Y) upstream of target genes [11].
ATF6a can initiate XBP1 expression [5], and can dimerise with
other transcription factors such as SRF [3], SREBP2 [12] and
CREB-H [13].
Recently, ER stress has been proposed to be involved in
ankylosing spondylitis (AS) [14], an arthritic condition in
which most suﬀerers express the HLA-B27 allele of the major
histocompatibility complex (MHC) class I family [15].
Although HLA-B27 homodimers at the cell surface may have
altered signaling properties [16,17], HLA-B27 can also misfold
in the ER and could trigger the UPR [18–20]. However, it is
not clear how UPR initiation might result in disease, or how
ﬁndings from animal models relate to the clinic. To investigate
whether MHC class I molecules cause an UPR in humans, we
have examined HeLa cells expressing misfolded HLA-B2705.
We ﬁnd that over expression of MHC class I heavy chains is
suﬃcient to induce the UPR and that HLA-B27 positive lym-
phocytes are pre-sensitised to XBP1 splicing compared to the
monocyte cell line THP1. Dithiothreitol, but not tunicamycin,
induces a long lasting UPR that culminates in the alternative
splicing of ATF6a in lymphocytes. Our results show that
UPR induction by faulty glycosylation and UPR induction
by disulﬁde bond reduction can be discriminated at the level
of both XBP1 processing and ATF6a transcription.2. Materials and methods
2.1. Cell lines and constructs
The human lymphoblastoid cell lines JESTHOM, HOM-2 (both
HLA-B2705) and WEWAK1(HLA-B2704) were obtained from the
ECACC. The human acute monocytic leukaemia cell line THP1 was
a gift from J. Robinson, Newcastle University, UK. These cell lines
were cultured in RPMI 1640 (Invitrogen). The human cervical carci-
noma cell line HeLa was maintained in minimum essential medium.
All cell lines were supplemented with 8% FCS, 100 units ml1 penicil-
lin, 100 lg ml1 streptomycin and 2 mM glutamax. The cDNA encod-
ing wild-type HLA-B2705 (conﬁrmed by DNA sequencing) and the
HC10 monoclonal antibody recognising free MHC class I heavy chains
were gifts from J. Neefjes, Netherlands Cancer Institute.blished by Elsevier B.V. All rights reserved.
Fig. 1. Induction of XBP1 processing by DTT and tunicamycin. (A)
Diagram illustrating the two expected mRNA/cDNA products of
XBP1, and their digestions by PstI. The unique PstI site is removed
when XBP1 is processed. (B) THP1 cells treated with (lanes 2–4) and
without (lane 1) 10 lg ml1 tunicamycin or with (lanes 6–8) and
without (lane 5) 10 mM DTT were lysed in TRI reagent, and the
lysates subjected to RT-PCR to detect XBP1. Resultant cDNA was
digested with PstI and analysed by 2% agarose gel to visualize the
activated spliced (S) and unspliced (U) products. Actin was used as a
control (lower panel).
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Suspension cells were grown to a density of 2–10 · 105 cells ml1
and resuspended with fresh medium containing 10 mM DTT or
10 lg ml1 tunicamycin to induce ER stress for given times. THP1 cells
were treated with 20 lg ml1 LPS for 4 days to induce partial diﬀeren-
tiation to adherent macrophages. Adherent HeLa cells were supple-
mented with 10 mM DTT or 10 lg ml1 tunicamycin for 6 h.
2.3. Cell transfections and lysis
HeLa cells in 6 cm dishes were transfected with 1 lg DNA in the
presence of 5 ll lipofectamine 2000 for 6 h in optiMEM (Invitrogen).
Cells were then provided with complete medium and analysed 24 h
post-transfection. Cells were lysed at 4 C in 300 ll MNT lysis buﬀer
(20 mMMES, 100 mM NaCl, 30 mM Tris, pH 7.4, supplemented with
20 mM N-ethylmaleimide (NEM), 1% Triton X-100 and 10 lg/ml each
of chymostatin, leupeptin, antipain, and pepstatin A). Post-nuclear
supernatants were taken up in sample buﬀer in the presence (reducing)
or absence (non-reducing) of 50 mM DTT and then subjected to 8%
SDS–PAGE.
2.4. Western blotting
Gels were wet transferred to polyvinylidene ﬂuoride (PVDF) mem-
branes (Millipore) for 2 h at 150 mA and the membranes were blocked
in 8% milk in PBS–Tween for 1 h. Membranes were incubated with
HC10 (1:200 tissue culture supernatant) for 1 h before being washed
ﬁve times with PBS–Tween. Membranes were then incubated with goat
anti-mouse peroxidase (GAMPO) secondary antibodies (DAKO) at
1:3000 for 1 h, and subsequently washed ﬁve times with PBS–Tween.
Proteins were then visualised with 200 ll enhanced chemiluminescence
ﬂuid (Amersham) per membrane and exposed to ﬁlm (Kodak).
2.5. Primers
The primers used for reverse transcriptase polymerase chain reaction
(RT-PCR) were as follows:
ATF6a: TGATGCCTTGGGAGTCAGAC and GTGTCAGA-
GAACCAGAGGCT.
XBP1: GAAACTGAAAAACAGAGTAGCAGC and GCTTCCAG-
CTTGGCTGATG.
Actin: CCACACCTTCTACAATGAGC and ACTCCTGCTTGCT-
GATCCAC.
2.6. RT-PCR, XBP1 analysis and sequencing of ATF6a
Cells were lysed in TRI reagent (Sigma) and the concentration of ex-
tracted, precipitated RNAwas determined by spectrophotometry. Fifty
nanograms total cell RNA was subjected to RT-PCR using the Access-
Quick RT-PCR kit (Promega). XBP1 cDNA was subjected to PstI
digestion for 2 h at 37 C and DNA extracted using a PCR puriﬁcation
kit (Qiagen). All cDNA was either analysed by 1% or 2% agarose gel at
100 mV for 50 min before visualising by UV light. ATF6a RT-PCR
products were puriﬁed using the QIAquick gel extraction kit (Qiagen)
and sequenced by the departmental sequencing centre. White-on-black
images were inverted in Adobe Photoshop.3. Results
3.1. Diﬀerential activation of XBP1 by DTT and tunicamycin
Prior to analyzing the relationship between HLA-B27 and
the UPR, we optimized UPR induction by stimulating the hu-
man monocyte cell line THP1 with either tunicamycin or DTT
for 0, 3, 6 and 24 h. We took advantage of the fact that activa-
tion (splicing) of XBP1 results in the removal of a unique PstI
site from the mRNA transcript [7]. Thus the UPR is activated
if a higher molecular weight (undigested) band is observed on
agarose gels after incubation of the cDNA with PstI. The frag-
ments expected from this digestion are explained in Fig. 1A. In
the absence of DTT or tunicamycin, XBP1 was not spliced,
resulting in a PstI sensitive product that was digested into
two fragments of 289 and 255 nucleotides (Fig. 1B, lanes 1
and 5). Both DTT and tunicamycin induced XBP1 mRNAprocessing in THP1 cells (Fig. 1B, lanes 2 and 6). However,
tunicamycin stimulation resulted in a resistant species that
ran as a doublet (S) and persisted as a singlet after 24 h
(Fig. 1B, lane 4). In contrast, DTT stimulation resulted in a
single resistant species that ran at the same height as the lower
band in the tunicamycin stimulated doublet (Fig. 1B, lanes 6–
8). THP1 cells partially recovered from tunicamycin stimula-
tion after 24 h, whereas in DTT stimulated cells, XBP1
remained processed after this time (Fig. 1, compare lanes 4
and 8), despite the fact that DTT is a labile reductant that
likely becomes oxidized in the culture medium. Lower concen-
trations of DTT also triggered the appearance of a single
XBP1 band (not shown). These results suggest that XBP1
splicing can follow more than one pathway, and that DTT
and tunicamycin can activate subtly diﬀerent processing or
RNA ligation events upstream of XBP1.
3.2. Misoxidised MHC class I heavy chains induce XBP1
processing in HeLa cells
UPR activation has been linked to misfolding of HLA-
B2705 heavy chains in a rat model of AS [14]. Thus we inves-
tigated whether misoxidised HLA-B2705 could activate the
UPR in HeLa cells. MHC class I heavy chains require both
an accessory light chain protein, b2m, and a peptide to fold
properly in the ER [21] and we have previously shown that
over expressed heavy chains misoxidise and form abundant
disulﬁde linked complexes in HeLa cells [22]. HeLa cells trans-
fected (or mock transfected) with HLA-B2705 were simulta-
neously lysed in the presence of the alkylating agent NEM to
preserve disulﬁde bonds or were taken up in TRI reagent for
Fig. 2. Misoxidised MHC class I heavy chains induce a tunicamycin-
like pathway of XBP1 processing. (A) HeLa cells transfected (lanes 1
and 3) or mock transfected (lanes 2 and 4) with HLAB2705 were lysed
24 h post-transfection and the supernatants subjected to non-reducing
(lanes 1 and 2) and reducing (lanes 3 and 4) 8% SDS–PAGE prior to
immunoblotting with HC10 to detect MHC class I protein heavy
chains. (B) HeLa cells treated for 6 h with (lane 1) or without (lane 2)
tunicamycin, with (lane 6) or without (lane 5) DTT, or 24 h post-
transfection with (lane 4) or without (lane 3) HLAB2705 were lysed
with TRI reagent and the mRNA subjected to RT-PCR and PstI
digest. 2% agarose gel electrophoresis was used to detect spliced (S)
and unspliced (U) XBP1 products. Actin was used as a positive control
(lower panel).
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PAGE, the HLA-B2705 transfected cells showed a ladder of
MHC class I complexes (Fig. 2A, lane 1), which could be re-
solved into a single species by adding DTT to reduce the sam-
ples (Fig. 2A, lane 3), conﬁrming that the MHC heavy chains
were misoxidised.
In THP1 cells, induction of the UPR by DTT resulted in a
single, activated XBP1 PstI resistant product, whereas activa-
tion of the UPR by tunicamycin resulted in a doublet (Fig. 1B,
compare lanes 2 and 6). In HeLa cells, treatment with DTT or
tunicamycin also induced the UPR and resulted in the genera-
tion of the same PstI resistant (active) forms of XBP1, showing
that diﬀerences in the processing of XBP1 were reproducible
between diﬀerent cell lines (Fig. 2B, lanes 1, 2, 5 and 6). Note
that the tunicamycin (S) doublet cannot be explained by
incomplete digestion or polymorphism at the PstI site because
there is no prominent (S) band in the undigested samples
(Fig. 2B, lane 1). In contrast to mock transfectants (Fig. 2B,
lane 3), HeLa cells expressing misoxidised HLA-B2705 gener-
ated XBP1 mRNA in the PstI resistant (activated) form. This
PstI resistant material appeared as a doublet (Fig. 2B, lane 4).
Thus misoxidation of MHC class I heavy chains is suﬃcient to
induce the UPR via a tunicamycin-like pathway of XBP1 splic-
ing.3.3. XBP1 processing in HLA-B27 positive lymphocytes
We next investigated the status of XBP1 in HLA-B27 typed
lymphoblastoid cell lines, one of which was HLA-B2704 posi-
tive (WEWAK1), and two of which were HLA-B2705 positive
(JESTHOM and HOM-2) and known to come from AS posi-
tive donors. We examined the sensitivity of these lymphocytes
to UPR induction with both tunicamycin and DTT (Fig. 3). As
a negative control, we used THP1 cells treated with of without
LPS only for 4 days. Both LPS and PMA stimulation are re-
quired to induce a UPR in monocytes [23]. LPS stimulated
the diﬀerentiation of THP1 to the adherent macrophage-like
state, but did not result in nonspeciﬁc activation of XBP1
(Fig. 3A, compare lanes 10 and 11). Compared with THP1
cells, WEWAK1, HOM-2 and JESTHOM all showed higher
levels of XBP1 splicing in the absence of any applied stimuli
(Fig. 3A, compare lanes 1, 4 and 7 with lane 10). DTT fully
activated XBP1 splicing in these cell lines (Fig. 3A, lanes 2, 5
and 8), whereas tunicamycin caused only a small increase com-
pared to the untreated control (Fig. 3A, lanes 3, 6 and 9). The
DTT induced splice form always ran at the level of the lower
band of the tunicamycin-induced doublet, consistent with
HeLa cells (Figs. 1 and 2) and THP cells (see Fig. 4).
To investigate these size diﬀerences further, the individual
PstI resistant PCR products obtained after treating HeLa cells
with DTT, or WEWAK1 cells with DTT or tunicamycin were
excised from 2% agarose gels, separated out (Fig. 3B) and re-
analysed for sequencing. The insertion resulting in the top
PCR product (Fig. 3B, lane 3) proved refractory to reproduc-
ible sequencing analysis, using a number of diﬀerent primer
sets (data not shown). However, the lower tunicamycin-in-
duced band (Fig. 3B, lane 4) was identical in sequence to the
DTT-induced PCR product (Fig. 3B, lanes 1 and 2), with an
excised 26 bp sequence bridging the PstI site (Fig. 3C). This re-
sult was conﬁrmed in both HeLa and WEWAK1 cells, and is
consistent with the literature [7]. We conclude from our exper-
iments that the lymphocyte cell lines examined have a higher
degree of baseline UPR activation than THP1 cells. XBP1 acti-
vation in these cells results in a novel PstI resistant splice form,
comparable to that induced by tunicamycin, rather than DTT.
Whether this eﬀect is caused by chronic, low-level misfolding
of HLA-B27, or is due to other factors will require further
investigations using fresh patient cells.3.4. Alternative splicing of ATF6a is induced by DTT
The diﬀerences between XBP1 processing induced by tunica-
mycin and DTT led us to investigate whether other branches of
the UPR were diﬀerently aﬀected by ER stress in lymphocytes
[24]. Unlike XBP1, activation of ATF6a occurs by liberating
an active transcription factor by proteolysis at the protein le-
vel. However, whilst examining RNA levels of ATF6a during
UPR, we found that an additional PCR product could be de-
tected in lymphoblastoid cells that had been treated with DTT,
but not in cells that had been treated with tunicamycin (Fig. 4).
This product was most prominent in WEWAK1 cells (Fig. 4A,
lane 2) but could also be detected in the AS cell line JES-
THOM (Fig. 4A, lane 8), and very weakly in HOM-2
(Fig. 4A, lane 5). This product was not detectable in nega-
tive-control (LPS stimulated) THP1 cells (Fig. 4A, lane 11)
or in DTT and tunicamycin-stimulated THP1 cells (Fig. 4B),
although XBP1 splicing could be induced by DTT and tunica-
mycin in the monocytic THP1 cell line (Fig. 4C).
Fig. 3. Activation of the UPR in HLA-B27 positive lymphoblastoid cell lines. (A) WEWAK1 (lanes 1–3), HOM-2 (lanes 4–6), JESTHOM (lanes 7–
9) and THP1 cells (lanes 10 and 11) were mock treated (lanes 1, 4, 7 and 10), treated with 10 mM DTT (lanes 2, 5 and 8) or 10 lg ml1 tunicamycin
(lanes 3, 6 and 9) for 6 h. THP1 cells treated with 20 lg ml1 LPS for 4 days were used as a negative control (lane 11). Cells were lysed in TRI reagent
and mRNAs were subjected to RT-PCR and PstI digest prior to 2% agarose gel electrophoresis to detect spliced (S) and unspliced (U) XBP1
products. (B) The discrete PstI resistant XBP1 PCR products from HeLa cells treated with 10 mM DTT (lane 1), and those from WEWAK1 cells
treated with 10 mM DTT (lane 2) or 10 lg ml1 tunicamycin (lanes 3 and 4) were re-analysed by 2% agarose gel electrophoresis. (C) The XBP1
products from (B) were sequenced, with lanes 1, 2 and 4 conﬁrmed as XBP1 with an excised 26 bp sequence in the region of the PstI site.
Fig. 4. Alternative splicing of ATF6a is induced by DTT. (A)
WEWAK1 (lanes 1–3), HOM-2 (lanes 4–6), JESTHOM (lanes 7–9)
and THP1 cells (lanes 10 and 11) were mock treated (lanes 1, 4, 7 and
10), or treated with 10 mM DTT (lanes 2, 5 and 8) or 10 lg ml1
tunicamycin (lanes 3, 6 and 9) for 6 h. THP1 cells treated with
20 lg ml1 LPS for 4 days were used as a negative control (lane 11).
mRNAs were subjected to RT-PCR and 2% agarose gel electropho-
resis to detect ATF6a products. (B) THP1 cells were mock treated
(lane 1), treated with 10 lg ml1 tunicamycin (lane 2) or 10 mM DTT
(lane 3) for 6 h, followed by lysis in TRI reagent and RT-PCR to detect
ATF6a (upper panel) and actin (lower panel) using 2% agarose gel
electrophoresis. (C) As for (B) but using RT-PCR to detect XBP1.
Fig. 5. The short form of ATF6a lacks exon 7. (A) The mRNA from
WEWAK1 cells stimulated for 6 h in the presence (lanes 2, 3 and 4) or
absence (lane 1) of 10 mM DTT was subjected to RT-PCR to detect
and isolate the short and conventional forms of ATF6a prior to
analysis by 2% agarose gel electrophoresis. (B) Sequence of the upper
band and lower band from (A) with both forward (F) and reverse (R)
primers. Bold type represents a section of the nucleotide sequence
present in the upper product and absent in the lower product,
corresponding to the known sequence of exon 7. The sizes of the
sequenced products are consistent with agarose gel analysis, where the
1 kb marker runs just above the major ATF6a product and the 0.75 kb
marker runs just below the short form. (C) Schematic diagram of the
ATF6a protein showing the amino acid sequence that is missing when
exon 7 is spliced out. TAD = transcription activation domain,
B = DNA binding domain, LZ = leucine zipper, dark shading = ER
transmembrane sequence, circles = glycosylation sites.
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termed (short) sATF6a, the upper and lower bands were cut
out from the agarose gel (Fig. 5A, lane 2), puriﬁed, reampliﬁed
by PCR (Fig. 5A, lanes 3 and 4) and sequenced. DNA
sequencing revealed that sATF6a lacked exon 7, but otherwise
was identical in sequence to the upper band, which matchedthe ATF6a sequence found in the database (Fig. 5B). This
alternative splicing event appeared speciﬁc to ATF6a, since
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primers for the ATF6a homolog ATF6b were used for RT-
PCR analysis (not shown). We conclude that induction of
the UPR by DTT (but not by tunicamycin) results in alterna-
tive splicing of ATF6a in lymphocytes. This creates a shorter
protein that lacks 75 amino acids at the boundary of the
DNA binding domain (Fig. 5C) and may be a novel partici-
pant in the regulation of the UPR.4. Discussion
We have shown that over-expression of MHC class I heavy
chains stimulates the UPR (Fig. 2). XBP1 shows some pre-
activation in three HLA-B27 expressing lymphoblastoid cell
lines, giving an induction pattern similar to that induced by
a glycosylation inhibitor (tunicamycin) rather than that in-
duced by a reductant of disulﬁde bonds (DTT) (Fig. 3). Our
results suggest that tunicamycin stimulation is a better mimic
of UPR induction by MHC class I misoxidation (Figs. 1 and
3). It will be important to determine the molecular signature
of the PstI resistant XBP1 species that is induced upon heavy
chain misoxidation or tunicamycin treatment. Whether it is
IRE1 RNase activity, or the two alternative mammalian ligase
activities, that give rise to these diﬀerent XBP1 products
should also be addressed by future experiments. Although
HLA-B2705 and HLA-B2704 are linked to AS, our results
do not point to a simple relationship between HLA-B27 and
UPR induction. It is more likely that there is a complex role
for the UPR in AS in vivo, where cytokines and the inﬂamma-
tory response are involved. Furthermore, professional antigen
presenting cells (e.g. dendritic cells) or endothelial cells at the
rheumatic joint may behave diﬀerently to the immortalized
lymphocytes examined here.
We have shown for the ﬁrst time that ATF6a is subject to
alternative splicing during reducing ER stress, but not during
tunicamycin-induced ER stress or in THP1 cells (Fig. 4). We
have sequenced sATF6a and shown that it lacks exon 7
(Fig. 5). The cell speciﬁcity, biological activity and precise
function of sATF6a remain to be determined. However, since
exon 7 lies at the start of the bZIP DNA binding domain, we
predict that the shortened form of the ATF6 protein may have
altered dimerisation and/or transcriptional activation proper-
ties. Although sATF6a is generated upon DTT treatment, cells
continue to express fulllength ATF6a. Thus redox stress does
not cause a complete switch from the full-length form to the
shorter form. Rather, sATF6a may compete with ATF6a to
reduce promoter occupancy, or could sequester ATF6a (as di-
mers) away from promoter elements. There is evidence that
both these mechanisms can regulate the mammalian UPR in
other circumstances: ATF6b has low transcriptional activity
[25], and represses ATF6a in competition experiments when
target gene expression is driven from an ERSE [26]. Unspliced
XBP1 can also regulate the activity of spliced XBP1 by target-
ing the XBP1 complex to the proteasome for degradation [27].
It is also possible that induction of sATF6a is involved in reg-
ulating entry into programmed cell death.
It is worth noting that endogenous alternatively spliced
ATF6a will not be detected by anti-tag antibodies commonly
used to identify ATF6a proteins in transfection experiments.
Thus a short form of ATF6a could explain some discrepanciesbetween UPR activation and mRNA levels of target tran-
scripts [28], particularly if DTT is used as a UPR inducer. Re-
cent work has shown that at the protein level, UPR
components react diﬀerently to assorted UPR activators [24].
Our experiments have revealed a hitherto unknown splicing
event that demonstrates that ATF6a is processed at both the
protein and mRNA level during an ER stress response. Given
that inﬂammation and the UPR can act synergistically [13], the
inability to reset the UPR after chronic stimulation may be an
important component of diseases such as AS, rather than sim-
ply the induction of the UPR itself.
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